We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

RNAi Used to Regulate Tumor Growth in Mouse Model

By Biotechdaily staff writers
Posted on 11 Feb 2003
Researchers have employed RNA interference (RNAi) technology to introduce changes in gene expression and "regulate” the severity of tumor development in an experimental mouse model. Their research was reported in the February 3, 2003, online edition of Nature Genetics.

Post-transcriptional gene silencing (PTGS), which was initially considered a bizarre phenomenon limited to petunias and a few other plant species, is now one of the most competitive topics in molecular biology. In the last few years, it has become clear that PTGS occurs in both plants and animals and has roles in viral defense and transposon silencing mechanisms. Perhaps most thought-provoking, however, is the emerging use of PTGS and RNA interference (RNAi)-- PTGS initiated by the introduction of double-stranded RNA (dsRNA)--as a tool to knock out expression of specific genes in a variety of organisms.

In the current study, investigators from Cold Spring Harbor Laboratory (NY, USA) studied the effect of RNAi on the p53 tumor suppressor gene. Mice with no active p53 develop lymphomas much sooner and in a more aggressive, highly invasive form than when the p53 gene is present.

The researchers reconstituted the blood cells of mice by first irradiating the animals to destroy their endogenous, bone marrow supply of hematopoietic stem cells, and then injected the mice with a fresh supply of hematopoietic stem cells that had been engineered through RNAi to produce low, medium, or high levels of p53.

Results showed that short hairpin RNAs (shRNAs) produced distinct phenotypes ranging from benign lymphoid hyperplasias to highly disseminated lymphomas. In all cases, the severity and type of disease correlated with the extent to which specific shRNAs inhibited p53 activity.

The authors concluded that, "RNAi can stably suppress gene expression in stem cells and reconstituted organs derived from those cells. Therefore, RNAi is a convenient alternative to traditional, laborious, and less flexible homologous recombination-based gene knockout strategies for studying the effects of reduced gene expression in a wide variety of settings.”




Related Links:
Cold Spring Harbor Laboratory

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Laboratory Software
ArtelWare

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
11 Feb 2003  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
11 Feb 2003  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
11 Feb 2003  |   BioResearch